SCHEMBL304397

SCHEMBL304397

O=C(c1ccc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2)cc1)N1CCc2ccccc2C1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 9/20 0.80
ALDH1A1 P00352 5/20 0.74
LMNA P02545 4/20 0.70
NPSR1 Q6W5P4 4/20 0.70
KMT2A Q03164 3/20 0.62
HTT P42858 3/20 0.60
OXTR P30559 2/20 0.60
AVPR1A P37288 2/20 0.60
MEN1 O00255 2/20 0.60
MAPT P10636 1/20 0.60
RECQL P46063 1/20 0.60
TP53 P04637 1/20 0.59
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58
PKM P14618 1/20 0.57
POLB P06746 1/20 0.54
PTGES O14684 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13065006 0.84 LMNA (0.91) HPGDALDH1A1LMNANPSR1KMT2A
SCHEMBL303420 0.84 LMNA (0.72) HPGDALDH1A1LMNAKMT2AHTT
SCHEMBL303307 0.81 LMNA (0.71) HPGDLMNAKMT2AHTTMEN1
SCHEMBL3456953 0.80 LMNA (0.79) HPGDALDH1A1LMNAKMT2AMAPT
SCHEMBL304361 0.79 LMNA (0.64) HPGDALDH1A1LMNAKMT2AHTT
SCHEMBL3275402 0.79 LMNA (0.64) HPGDLMNAKMT2AHTTAVPR1A
SCHEMBL3455229 0.79 HPGD (0.82) HPGDALDH1A1LMNANPSR1KMT2A
SCHEMBL13065007 0.78 LMNA (0.86) HPGDALDH1A1LMNANPSR1KMT2A
SCHEMBL304251 0.77 LMNA (0.62) HPGDALDH1A1LMNAKMT2AMEN1
SCHEMBL13064487 0.77 LMNA (0.69) HPGDALDH1A1LMNAKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
JP-2012500834-A 2012-01-12 JP claimed
EP-2344456-A1 NOVEL POTASSIUM CHANNEL BLOCKER Xention Limited (GB) 2011-07-20 EP claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 HPGD 3739/4885ALDH1A1 1588/4885LMNA 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.